

MELOXIWAY ORAL SUSPENSION FOR CATS

Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders such as discospondylosis, arthropathy and soft tissue injuries.

ACTIVE CONSTITUENT:
0.5 mg/mL Meloxicam

NET CONTENTS:
10 mL
30 mL
100 mL

DIRECTIONS FOR USE:
Use as directed by prescribing veterinarian

RESTRAINTS:
DO NOT USE in food-producing species of animals.

CONTRAINDICATIONS:

Contraindicated for use in cats less than 6 weeks of age.

Contraindicated for use in pregnant or lactating animals.

Contraindicated for use in animals suffering from cardiac, hepatic or clinical renal disease. Especially older cats considered for chronic treatment should be screened for pre-existing renal, hepatic or gastrointestinal disorders or hypovolaemia (using haematology, serum, biochemical analysis and urinalysis as necessary), before administration of Meloxiway Oral Suspension for Cats.

Contraindicated for use in any dehydrated, hypovolaemic or hypotensive animal as there is the potential risk of renal toxicity.

Contraindicated for use in animals where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a haemorrhagic disorder or individual hypersensitivity to the product.

DOSAGE & ADMINISTRATION:

Shake well before use.

Use the contents within 3 months of first broaching the container. Discard the unused portion.

Should be administered orally either mixed with food or directly into the mouth around mealtimes.

Initial treatment is a single dose of 0.1 mg meloxicam / kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24 h intervals) at maintenance dose of 0.05 mg/kg bodyweight.

	Dose Rate	Volume
Initial Dose (First day of treatment)	0.1 mg/kg body weight	0.2 mL/kg body weight
Maintenance dose	0.05 mg/kg body weight	0.1 mL/kg body weight



Particular care should be given with regard to the accuracy of dosing. A 1 mL syringe is included in the package to assist with dose measurement and administration. The recommended dose should not be exceeded.

Dosing procedure using the measuring syringe.

Shake the bottle vigorously. Unscrew the cap and attach the dosing syringe to the bottle by gently pushing the syringe end into the insert at the top of the tube to ensure a good seal. Invert the bottle and draw the plunger until the black line on the plunger corresponds to the volume required in mL. Turn the bottle right way up and with a twisting motion, gently separate the dosing syringe from the bottle. Position the syringe directly over the food or in the mouth. Gently press the plunger in to dispense the dose.

A clinical response is normally seen within 7 days. Where treatment is continued for more than 7 days, cats should be closely monitored for adverse effects. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.

GENERAL DIRECTIONS:

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) compound of the oxicam group which acts by inhibition of prostaglandin synthesis. Meloxicam exerts anti-inflammatory, anti-exudative, analgesic and antipyretic. It inhibits leukocyte infiltration into the inflamed tissue and prevents bone and cartilage destruction. To a minor extent it also inhibits collagen-induced thrombocyte aggregation.

PRECAUTIONS:

Meloxiway Oral Suspension for Cats should not be administered concurrently with steroidal or other non-steroidal anti-inflammatory drugs, aminoglycoside antibiotics or anticoagulant agents. Concurrent administration of potential nephrotoxic drugs should be avoided.

Pre-treatment with anti-inflammatory drugs may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with Meloxiway Oral Suspension for Cats. The treatment-free period, however, should take into account the pharmacokinetic properties of the drugs used previously.

Response to a long-term therapy should be monitored at three monthly intervals or more frequently as advised by the veterinarian.

Meloxiway Oral Suspension for Cats should not be used following parenteral injection of Meloxicam or any other NSAID as appropriate dosage regimens for such follow-up treatments have not been established.

The use of this product in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided careful clinical management may be required.

SIDE EFFECTS:

Typical adverse reactions of NSAIDs may occur. These may include loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure. Gastro-intestinal side effects are in most cases transient and disappear following termination of treatment but in rare cases may be serious. If gastro-intestinal side effects are persistent or of severity, treatment should be discontinued.

In the event of an overdose, adverse reactions are expected to be more severe and more frequent. In case of overdosing a symptomatic treatment should be initiated.



SAFETY DIRECTIONS:

Harmful if swallowed. May irritate the eyes and skin. Avoid contact with eyes and skin. When using this product wear disposable gloves. Wash hands after use.

FIRST AID INSTRUCTIONS:

If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 13 11 26.

ADDITIONAL USER SAFETY:

Pregnant women and people with known hypersensitivity to NSAIDs should avoid contact with meloxicam. If the medicine comes into contact with the skin, the affected area should be rinsed thoroughly.

DISPOSAL

Dispose of container by wrapping in paper and putting in the garbage.

STORAGE

Store below 25°C (air conditioning).

APVMA Approval No. 89799/135598

